MT Newswires5d agobullish
UBS Adjusts Price Target on Vertex Pharmaceuticals to $640 From $615, Maintains Buy RatingNews
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
105last 24h
3127last 7d
510● bullish (7d)
311● bearish (7d)
227publishers
MT Newswires5d agobullish
RBC Raises Price Target on Vertex Pharmaceuticals to $600 From $576, Keeps Outperform Rating